1. < Home

Checkpoint Inhibitor

Therapeutic Advances in Advanced Basal Cell Carcinoma

Alkassis S, Shatta M, Wong DJ. Therapeutic Advances in Advanced Basal Cell Carcinoma. Cancers (Basel). 2024 Sep 4;16(17):3075. doi: 10.3390/cancers16173075. PMID: 39272933; PMCID: PMC11394629.

By sjmartinez • September 15, 2024
Pembrolizumab-induced nephrotoxicity in a patient with breast cancer

Alkassis S, Fitzsimmons K, Hurvitz S. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241248362. doi: 10.1177/17588359241248362. PMID: 38680292;[...]

By sjmartinez • April 29, 2024
POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval

Bikhchandani M, Amersi F, Hendifar A, Gangi A, Osipov A, Zaghiyan K, Atkins K, Cho M, Aguirre F, Hazelett D, Alvarez R, Zhou L, Hitchins[...]

By sjmartinez • May 28, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

Johnson ML, Strauss J, Patel MR, Garon EB, Eaton KD, Neskorik T, Morin J, Chao R, Halmos B. Mocetinostat in Combination With Durvalumab for Patients[...]

By sjmartinez • March 9, 2023
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ,[...]

By sjmartinez • September 27, 2022